Not a member? Register.
Uma Jeunesse is manufactured by Cambridge Medical Aesthetics Ltd., part of Cambridge Biotech Ltd, a company founded in 1999, which is based in Cambridgeshire, England.
It is marketed as the next revolutionary step in dermal fillers, optimising volume and contouring in the face, lips, and nose for facial rejuvenation. It was introduced to the UK market in December 2014.
It is a hyaluronic acid based dermal filler aimed at treating lines and wrinkles, naso-labial (nose to mouth) lines, marionette (mouth to chin) lines, sagging cheeks, as well as contouring lips, temples and noses. The product can also be used for treating facial defects and for hand rejuvenation.
Cross-linked non-animal hyaluronic acid, made from the streptococcus equi bacteria.
Uma Jeunesse features the company’s patented DXN® technology to produce a cross-linked hyaluronic acid (HA) dermal filler of non-animal origin. The DXN creates extra bridges when making the cross-linked hyaluronic acid which gives an extra solid matrix or structure to the resulting HA gel; a double cross-linking effect. This means that the molecules of the gel adapt to the shape of the tissues where they are placed.
The ULTRA product also contains the local anaesthetic ingredient lidocaine for added comfort when injecting deeply.
No skin test is required before injection of the product. Hyaluronic acid is naturally present in the body and the product will be metabolised over time.
European CE marked medical device.
Uma Jeunesse should only be administered by trained medical professionals.
There are a number of different formulations of Uma Jeunesse available. Your practitioner will advise which specific one is best suited to what you are aiming to achieve in terms of facial rejuvenation.
Uma Jeunesse CLASSIC®, available in 1ml and 2ml syringes with 24mg/ml of hyaluronic acid. It is used to treat moderate to deep facial lines, for lip and nose augmentation (non-surgical rhinoplasty or nose job), facial and body defects and hand rejuvenation.
Uma Jeunesse VELVET®, is a lighter alternative, which can be used as a mesotherapy technique. This product is available in 1ml syringes and ideal for fine lines, wrinkles around the mouth (smoker’s lines), bags under the eyes (tear troughs), lip rejuvenation and skin improvements.
Uma Jeunesse ULTRA®, features the added ingredient of lidocaine, a local anaesthetic for added comfort during administration. This product treats medium to deep facial lines and for nose and lip augmentation.
Patients with a history of anaphylaxis, bleeding disorders, or multiple severe allergies should not be treated. It also contains minute amounts of gram-positive bacterial proteins, so patients with a history of allergies to these substances also should not be treated.
Pregnant and breast feeding women are not suitable for treatment.
According to the manufacturer, the Uma Jeunesse CLASSIC product has a lasting effect of between 9-12 months.
Expect temporary erythema or redness, pain, swelling, itching, discolouration or tenderness at the injection points. This should resolve in 1 or 2 days, but symptoms may last up to 7 days depending on the location of the treatment.
It is biodegradable and biocompatible with skin tissue so will disappear over time as it is metabolised by the body. The company reports minimal side effects from use of its products.
The price range for Uma Jeunesse varies depending on the areas treated, the product used and the number of syringes required. The price range is from £110 to £300 per syringe.
The makers claim that one of the advantages of their products is that they can be up to a third cheaper than other leading brands, offering an additional benefit to price sensitive clients.
Lip augmentation, before (left), after (right)
Naso-labial folds, before (left), after (right)
Non-surgical rhinoplasty (nose job), before (left), after (right)
(Before and after photographs are real patients, your results may differ).
Photos provided courtesy of Cambridge Medical Aesthetics Ltd
During a 10-month clinical trial, held at various centres within the UK, Uma Jeunesse was administered to 38 patients, where it was proven to be safe and effective. The most common side effect was a response of redness, swelling, tenderness and bruising at the injection sites, with no adverse reactions reported. This trial also showed what is referred to as ‘clinically significant improvement in the severity’ of naso-labial folds after 1 to 3 weeks post treatment. On average results were shown to last 9 months.
Another 9-month randomised, controlled study compared Uma Jeunesse to another product, Juvéderm Ultra. This study looked at 17 patients who had one naso-labial fold on each side of their face injected with each product brand for comparison. Information such as patient experience (satisfaction), pain or discomfort and reactions were then recorded. Uma Jeunesse showed a reduction in the severity of all the key post treatment markers of swelling, pain, redness, itching, bruising etc. in comparison with the Juvéderm Ultra.